MacuClear Inc. has tossed its hat into the age-related macular degeneration (AMD) ring with the first of two pivotal Phase III studies for lead compound MC-1101. The topically administered drug, delivered as an eye drop, is designed to treat and stop the progression of AMD from early stage, or the dry form, to late-stage, or wet AMD, by increasing ocular blood flow in the choroidal vessels.